


11MAG2

RCE/1634
\$



Request For Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	09/879,217
Filing Date	June 13, 2001
First Named Inventor	Kathleen D. DANENBERG
Art Unit	1634
Examiner Name	Jeffrey Fredman
Attorney Docket Number	11220/129

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 C.F.R. 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
ii. ☐ Other

b. ☒ Enclosed

- i. ☒ Amendment/Reply
ii. ☐ Affidavit(s)/Declaration(s)
iii. ☐ Information Disclosure Statement (IDS)
iv. ☐ Other

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. 1.17(i) required)
b. ☐ Other

3. **Fees** The RCE fee under 37 C.F.R. 1.17(e) is required by 37 C.F.R. 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 11-0600
i. ☒ RCE fee required under 37 C.F.R. 1.17(e)
ii. ☒ Extension of time fee (37 C.F.R. 1.136 and 1.17)
iii. ☐ Other
b. ☐ Check in the amount of \$ _____ enclosed
c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print /Type)	Thomas A. Haag, Ph.D.	Registration No. (Attorney/Agent)	47,621
Signature		Date	July 29, 2003

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below:

Name (Print /Type)			
Signature		Date	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
DOCKET NO.: 11220/129

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Danenberg, Kathleen D.

Serial No.: 09/879,217

Filing Date: June 13, 2001

For: METHOD OF DETERMINING
DIHYDROPYRIMIDINE
DEHYDROGENASE GENE EXPRESSION

Art Unit: 1634

Examiner: Jeffrey Fredman

Assistant Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE FILED UNDER 37 C.F.R § 1.114

Sirs:

This is in response to a the Final Office Action mailed on February 14, 2003 and is filed with a Request for Continued Examination along with a one-month Extension of Time from the date that an Appeal Brief was due, June 29, 2003. No new matter is raised.

In The Claims:

Please amend the claims as follows:

12. (Twice Amended) A method for determining a 5-Fluorouracil-based chemotherapeutic regimen for treating a tumor in patient comprising:

- (a) obtaining a tumor sample from the patient;
- (b) isolating mRNA from said tumor sample;
- (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers SEQ ID: 1, or an oligonucleotide primer at least 80% identical therewith and hybridizes to a complement of SEQ ID NO: 1 under stringent conditions; wherein said isolated and purified oligonucleotide is capable of amplifying a portion of the 5' untranslated region and Exon 1 of a *Dihydropyrimidine Dehydrogenase (DPD)* mRNA isolated from fixed and paraffin embedded (FPE) tissue when used with SEQ ID NO: 2, and